Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

4.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.

5.

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators.

Lancet. 2004 Jul 24-30;364(9431):331-7.

PMID:
15276392
6.

Clopidogrel: a review of its use in the prevention of atherothrombosis.

Jarvis B, Simpson K.

Drugs. 2000 Aug;60(2):347-77. Review. Erratum in: Drugs 2001;61(1):52.

PMID:
10983738
8.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

10.
11.

Clopidogrel for cerebrovascular prevention.

Paciaroni M, Bogousslavsky J.

Cerebrovasc Dis. 1999 Sep-Oct;9(5):253-60. Review.

PMID:
10473907
12.

Clopidogrel: new preparation. An alternative to aspirin.

[No authors listed]

Prescrire Int. 1999 Dec;8(44):163-4.

PMID:
11503810
13.

Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD001246. doi: 10.1002/14651858.CD001246.pub2. Review.

PMID:
19821273
14.
15.

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.

Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E, Wolf PA.

Clin Cardiol. 1999 Sep;22(9):559-73. Review.

16.

Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.

Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ.

Cerebrovasc Dis. 2004;17(2-3):253-61. Epub 2004 Feb 23.

PMID:
14981346
17.

[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].

Scheen AJ.

Rev Med Liege. 2001 Mar;56(3):186-9. French.

PMID:
11338792
18.

Role of antiplatelet drugs in the prevention of cardiovascular events.

Tendera M, Wojakowski W.

Thromb Res. 2003 Jun 15;110(5-6):355-9. Review.

PMID:
14592562
20.

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.

Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W; Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators.

Stroke. 2004 Feb;35(2):528-32. Epub 2004 Jan 22.

Supplemental Content

Support Center